CA3242612A1 - Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions - Google Patents

Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions

Info

Publication number
CA3242612A1
CA3242612A1 CA3242612A CA3242612A CA3242612A1 CA 3242612 A1 CA3242612 A1 CA 3242612A1 CA 3242612 A CA3242612 A CA 3242612A CA 3242612 A CA3242612 A CA 3242612A CA 3242612 A1 CA3242612 A1 CA 3242612A1
Authority
CA
Canada
Prior art keywords
purine
piperidinyl
enriched
amines
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3242612A
Other languages
English (en)
French (fr)
Inventor
Terrence Joseph Connolly
Chad Arthur LEWIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
K36 Therapeutics Inc
Original Assignee
K36 Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by K36 Therapeutics Inc filed Critical K36 Therapeutics Inc
Publication of CA3242612A1 publication Critical patent/CA3242612A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3242612A 2022-01-05 2023-01-05 Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions Pending CA3242612A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263296676P 2022-01-05 2022-01-05
US63/296,676 2022-01-05
PCT/US2023/010204 WO2023133201A1 (en) 2022-01-05 2023-01-05 Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions

Publications (1)

Publication Number Publication Date
CA3242612A1 true CA3242612A1 (en) 2023-07-13

Family

ID=87074217

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3242612A Pending CA3242612A1 (en) 2022-01-05 2023-01-05 Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions

Country Status (10)

Country Link
US (2) US12492203B2 (enExample)
EP (1) EP4460502A4 (enExample)
JP (1) JP2025504379A (enExample)
KR (1) KR20240158230A (enExample)
CN (1) CN119032094A (enExample)
AU (1) AU2023205553A1 (enExample)
CA (1) CA3242612A1 (enExample)
IL (1) IL314062A (enExample)
MX (1) MX2024008450A (enExample)
WO (1) WO2023133201A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021026803A1 (en) 2019-08-14 2021-02-18 Novartis Ag Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
CN120641105A (zh) * 2022-12-12 2025-09-12 K36治疗股份有限公司 含有哌啶基甲基嘌呤胺的药物组合物及其在治疗疾病和疾患中的用途
AU2024381513A1 (en) * 2023-11-17 2026-06-04 K36 Therapeutics, Inc. Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
CN117843641B (zh) * 2023-12-28 2025-04-25 和径医药科技（上海）有限公司 Nsd3抑制剂及其制备方法和应用
WO2025259850A1 (en) * 2024-06-12 2025-12-18 K36 Therapeutics, Inc. Pharmaceutical compositions containing a deuterium-enriched piperidinyl-methyl-purine amine and their use in treating diseases and conditions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ591615A (en) 2008-09-18 2012-07-27 Auspex Pharmaceuticals Inc Benzoquinoline inhibitors of vesicular monoamine transporter 2
EP2463289A1 (en) * 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
WO2021026803A1 (en) 2019-08-14 2021-02-18 Novartis Ag Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
CN114981270B (zh) 2019-09-20 2024-10-18 诺华公司 Mll1抑制剂和抗癌剂
AR122159A1 (es) 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
US20250326752A1 (en) 2022-05-18 2025-10-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
JP2025517349A (ja) 2022-05-18 2025-06-05 ケイ３６・セラピューティクス・インコーポレイテッド ピペリジニル－メチル－プリンアミンｄ－酒石酸塩、結晶形態、ならびに医学的疾患及び状態の治療におけるそれらの使用
WO2023225144A1 (en) 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023225150A1 (en) 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023230038A1 (en) 2022-05-23 2023-11-30 K36 Therapeutics, Inc. Piperidinyl-methylpurine pyrimidines and related compounds and their use in treating diseases and conditions
US20250361235A1 (en) 2022-05-23 2025-11-27 K36 Therapeutics, Inc. Piperidinyl-methylpurine benzenes and related compounds and their use in treating diseases and conditions
WO2024055048A1 (en) 2022-09-09 2024-03-14 The Trustees Of Columbia University In The City Of New York Methods of treating neuroendocrine prostate cancer (nepc) by inhibiting nuclear receptor binding set domain protein 2 (nsd2)
CN120641105A (zh) 2022-12-12 2025-09-12 K36治疗股份有限公司 含有哌啶基甲基嘌呤胺的药物组合物及其在治疗疾病和疾患中的用途
AU2024381513A1 (en) 2023-11-17 2026-06-04 K36 Therapeutics, Inc. Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions

Also Published As

Publication number Publication date
EP4460502A1 (en) 2024-11-13
US20260049083A1 (en) 2026-02-19
MX2024008450A (es) 2024-12-06
CN119032094A (zh) 2024-11-26
US20240352017A1 (en) 2024-10-24
JP2025504379A (ja) 2025-02-12
AU2023205553A1 (en) 2024-07-25
WO2023133201A1 (en) 2023-07-13
US12492203B2 (en) 2025-12-09
KR20240158230A (ko) 2024-11-04
IL314062A (en) 2024-09-01
EP4460502A4 (en) 2025-12-24

Similar Documents

Publication Publication Date Title
MX2021004431A (es) Procesos novedosos.
EP4548918A3 (en) Tricyclic compounds as inhibitors of kras
CR20240003A (es) Restos de administración terapéutica novedosos y usos de estos
EP4356973A3 (en) 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer
WO2024120378A3 (en) Triazole compounds, preparation methods and medicinal uses thereof
MX2023003564A (es) Compuestos y su uso en el tratamiento del cancer.
EP4356975A3 (en) Erbb/btk inhibitors
MX2024014117A (es) Sales de ácido piperidinil-metil-purina-amina-d-tartárico, formas cristalinas y su uso en el tratamiento de enfermedades y condiciones médicas
MX2022011697A (es) Inhibidores de ciclofilina y usos de los mismos.
PH12019500214A1 (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
MX2025006740A (es) Composiciones farmacéuticas que contienen una de piperidinil-metil-purina amina y su uso en el tratamiento de enfermedades y afecciones
MX2024008450A (es) Piperidinil-metil-purina aminas enriquecidas con deuterio y compuestos relacionados y su uso en el tratamiento de enfermedades y condiciones
MX2025003515A (es) Moduladores de akt1
WO2024026129A3 (en) Tricyclic aryl derivatives, and compositions and methods thereof
WO2024243304A3 (en) Bicyclic heteroaryl compounds
MX2024015581A (es) Derivados de anilino-pirazol, composiciones y metodos de estos
WO2022106902A8 (en) Benzenesulfonamide derivatives and uses thereof
MX2023003516A (es) Inhibidores no covalentes de la cinasa dependiente de ciclina 7 (cdk7).
MX2025014320A (es) Compuestos nitrogenados aromaticos, metodos de preparacion y usos medicinales
MX2023014547A (es) Proceso para la preparacion de inhibidores de familia de receptores tipo nod con dominio pirina 3 (nlrp3).
PH12021550258A1 (en) Cdk8/19 inhibitors
WO2025189056A8 (en) Heterobifunctional compounds and their use in treating disease
TW200628473A (en) Novel heterocycles
MX2009007889A (es) Derivados de 3-cinnolincarboxamida y su uso para el tratamiento del cancer.

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241227

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241227

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241227

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251229

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251229